Sonic Healthcare: the pathology giant most Australians have never heard of

Next time you have blood drawn at a suburban collection centre in Sydney, or your GP sends off a swab in Frankfurt, or a hospital in Delaware needs a biopsy read overnight, there's a fair chance the same Australian company is somewhere in that chain. Sonic Healthcare is one of the largest medical laboratory businesses on the planet, and I'd bet most people reading this have never consciously registered its name. That's rather the point of an invisible giant, and it's why this masthead keeps coming back to companies like it.

I've spent a fair bit of time this year going through ASX healthcare filings for this series, and Sonic keeps popping up in the background of stories about other things — a German lab acquisition here, a US pathology tender there. It rarely makes headlines the way a mining stock or a bank does. But strip away the noise and you've got a company operating in eight countries, processing an enormous volume of pathology and radiology tests annually, with a market capitalisation that regularly sits among the largest on the Australian exchange. That's not a niche operator. That's a genuine multinational hiding in plain sight, in the same mould as Computershare or Brambles — Australian firms that became indispensable to systems most of us never think about until something goes wrong.

From a single Sydney lab to a global pathology network

Sonic's story starts modestly, as these stories usually do. The company's roots trace back to a group of pathology practices around Sydney in the latter half of the twentieth century, consolidated under what eventually became Sonic Healthcare in the 1990s under the stewardship of Dr Colin Goldschmidt, the scientist-turned-chief-executive whose long tenure running the company is unusual in ASX 200 land, where CEO turnover tends to be brisk. Goldschmidt trained as a pathologist himself, which matters — this isn't a finance executive who wandered into healthcare because the margins looked attractive. It's someone who understood the clinical side of the business before he ever understood the balance sheet.

The expansion strategy that followed was patient and, frankly, a bit unglamorous: buy well-run regional and national pathology laboratories, keep the local management and brand where it made sense, and bolt them onto a shared administrative and technology backbone. Sonic did this first across Australia, then moved into the United States, the United Kingdom, Germany, Switzerland, and other European markets through a long string of acquisitions spanning more than two decades. It's the same playbook Reece used in America with plumbing supply — buy the trusted local operator, don't blow up what already works, let the network effects do the heavy lifting over time.

Why pathology is a genuinely hard business to compete in

It's worth explaining why this particular industry rewards scale the way it does, because it's not obvious from the outside. A pathology network needs enormous capital investment in analysers, information systems, and logistics — samples have to move from collection centres to labs within tight time windows, sometimes measured in hours, and results have to flow back into hospital and GP systems without errors. Regulatory frameworks governing laboratory accreditation, quality assurance, and data handling differ by country and are not trivial to navigate; in Australia, for instance, labs operate under National Association of Testing Authorities accreditation and Medicare-linked billing rules that shape almost everything about how a pathology business is run.

Scale lets you spread that fixed cost of automation and compliance across a much larger volume of tests, which is precisely why the industry globally has consolidated into a handful of large players rather than staying fragmented among thousands of small local labs. Sonic, LabCorp and Quest Diagnostics in the US, and a scattering of European operators are effectively the industry now. That's a genuinely difficult moat to build from scratch, and it's a big part of why Sonic's international growth has come almost entirely through acquisition rather than greenfield expansion.

The pandemic put a spotlight on an ordinarily unglamorous business

For a company that spent decades operating well below the public radar, the COVID-19 pandemic was the closest thing to a mainstream moment Sonic has had. Laboratory testing capacity became, briefly, a matter of national significance, and Sonic's networks across Australia, the US and Europe were pressed into large-scale PCR testing programmes. Revenue and earnings spiked accordingly during the pandemic years, as reported in the company's ASX filings, before settling back toward a more typical base-business trajectory as testing volumes normalised. I'd argue that period slightly distorted how outsiders perceive the company's underlying growth rate — some of the enthusiasm baked into the share price during 2021 was always going to unwind once mass testing contracts wound down, and it has.

What's more instructive, in my view, is what happened to the base pathology and radiology business once the pandemic bump faded. It kept growing, if less dramatically, on the back of ageing populations across its core markets and the steady, unglamorous demand for routine blood work, cancer screening and chronic disease monitoring that underpins the entire industry. That's the real story of Sonic — not a pandemic windfall, but decades of unspectacular, compounding growth in a service nobody notices until they need it.

A genuinely global footprint most ASX investors underrate

Here's a detail that surprises people when I bring it up: a meaningful share of Sonic's revenue now comes from outside Australia, with Germany and the United States among its largest markets by scale. This isn't a domestic champion that dabbles overseas. It is a company where the offshore operations are, in aggregate, as consequential as the home base, run by local management teams under a lightly-touch corporate structure out of Sydney. That's a genuinely rare thing for an Australian-listed company to have pulled off in a clinical, heavily regulated services industry, as opposed to resources or agriculture where Australia's comparative advantages are more obvious.

The Swiss and German operations, built up through a series of acquisitions of established local laboratory groups, are a particularly good example of the model — Sonic didn't try to export an Australian pathology brand into central Europe. It bought respected local operators, kept their clinical reputations intact, and layered its own systems and purchasing scale underneath. It's a less flashy version of internationalisation than the one usually celebrated in business commentary, but it has proven durable.

Where the risks actually sit

None of this means Sonic is a company without genuine pressure points, and I don't think admiring the growth story should mean ignoring them. Government reimbursement policy is the biggest one. Pathology billing in markets like Australia and the US is heavily shaped by public health funding rules, and changes to Medicare rebate schedules or US reimbursement policy under frameworks like Medicare's Clinical Laboratory Fee Schedule can compress margins quickly and with little warning. Sonic doesn't set its own prices in the way a typical consumer business does; a great deal of its revenue is effectively negotiated with, or set by, government payers.

There's also the ongoing question of automation and consolidation risk — the same scale advantages that let Sonic dominate can, in theory, be replicated by a well-capitalised competitor or an aggressive hospital-system vertical integration push in any one of its markets. I don't think that's an imminent threat, but it's the kind of structural risk worth watching rather than assuming away.

The quiet compounding that defines the whole sector

What I keep coming back to, having now written about several of these Australian global operators for this section, is how similar the underlying pattern is. Ansell quietly became a global glove and protective-equipment leader off the back of Dunlop's old rubber know-how. Brambles turned a wooden pallet into a worldwide logistics standard. Computershare ended up running share registries most of the world doesn't know exist. Sonic Healthcare fits the same mould: an unglamorous, essential service, built through patient acquisition and operational discipline rather than a single dazzling breakthrough, that ended up genuinely global almost by accident of good management sustained over a very long time.

It's not a thrilling story to tell at a dinner party. But if you want to understand how Australian companies actually win overseas — not with a single hit product, but with decades of unglamorous execution in an industry everyone else finds boring — Sonic is close to the ideal case study. I'll keep watching the reimbursement settings in its three biggest markets, because that's genuinely where the next surprise, good or bad, is most likely to come from.